CA3046809A1 - Non-peptide oxytocin receptor agonists - Google Patents

Non-peptide oxytocin receptor agonists Download PDF

Info

Publication number
CA3046809A1
CA3046809A1 CA3046809A CA3046809A CA3046809A1 CA 3046809 A1 CA3046809 A1 CA 3046809A1 CA 3046809 A CA3046809 A CA 3046809A CA 3046809 A CA3046809 A CA 3046809A CA 3046809 A1 CA3046809 A1 CA 3046809A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3046809A
Other languages
English (en)
French (fr)
Inventor
Michael Kassiou
William Jorgensen
Eryn Werry
Tristan Reekie
Michael Bowen
Iain McGregor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinoxis Therapeutics Pty Ltd
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905126A external-priority patent/AU2016905126A0/en
Application filed by University of Sydney filed Critical University of Sydney
Publication of CA3046809A1 publication Critical patent/CA3046809A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CA3046809A 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists Pending CA3046809A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905126A AU2016905126A0 (en) 2016-12-12 Non-peptide oxytocin receptor agonists
AU2016905126 2016-12-12
PCT/AU2017/051371 WO2018107216A1 (en) 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists

Publications (1)

Publication Number Publication Date
CA3046809A1 true CA3046809A1 (en) 2018-06-21

Family

ID=62557695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3046809A Pending CA3046809A1 (en) 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists

Country Status (19)

Country Link
US (2) US11491165B2 (https=)
EP (2) EP4494705A3 (https=)
JP (3) JP7089649B2 (https=)
KR (1) KR102561721B1 (https=)
CN (1) CN110248944A (https=)
AU (1) AU2017377653B2 (https=)
BR (1) BR112019012049A2 (https=)
CA (1) CA3046809A1 (https=)
DK (1) DK3551631T3 (https=)
ES (1) ES3001195T3 (https=)
FI (1) FI3551631T3 (https=)
HU (1) HUE070078T2 (https=)
IL (1) IL267276B2 (https=)
MX (1) MX2019006942A (https=)
PL (1) PL3551631T3 (https=)
PT (1) PT3551631T (https=)
RU (1) RU2019120162A (https=)
SI (1) SI3551631T1 (https=)
WO (1) WO2018107216A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079953A1 (en) * 2018-11-23 2022-03-17 The University Of Sydney Methods for management of weight
KR20220063198A (ko) * 2019-09-06 2022-05-17 키녹시스 테라퓨틱스 피티와이 리미티드 아편유사제 금단의 치료
JP2022548581A (ja) 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
JP2023552485A (ja) * 2020-12-14 2023-12-15 キノシス・セラピューティクス・ピーティーワイ・リミテッド オキシトシン受容体モジュレーター
AU2022240104A1 (en) * 2021-03-18 2023-10-05 Kinoxis Therapeutics Pty Ltd Methods of treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770762A (en) * 1972-08-29 1973-11-06 Parke Davis & Co Diazepine compounds and methods for their production
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
EP1449844A1 (en) * 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
US7342112B2 (en) * 2003-07-01 2008-03-11 Ppg Industries Ohio, Inc. Photochromic compounds
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
CN101203516A (zh) * 2005-04-05 2008-06-18 法马科皮亚公司 用于免疫抑制的嘌呤及咪唑并吡啶衍生物
AU2006306547A1 (en) 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists
WO2008103382A1 (en) * 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same
GB0903493D0 (en) * 2009-02-27 2009-04-08 Vantia Ltd New compounds
US10508108B2 (en) * 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
PL3328864T3 (pl) * 2015-07-06 2023-02-27 Kinoxis Therapeutics Pty Ltd Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych

Also Published As

Publication number Publication date
CN110248944A (zh) 2019-09-17
KR102561721B1 (ko) 2023-07-28
US20200000823A1 (en) 2020-01-02
IL267276B1 (en) 2024-05-01
BR112019012049A2 (pt) 2019-11-12
EP3551631A1 (en) 2019-10-16
AU2017377653B2 (en) 2022-04-21
JP2024107136A (ja) 2024-08-08
EP3551631A4 (en) 2020-07-15
JP2022097655A (ja) 2022-06-30
RU2019120162A (ru) 2021-01-12
ES3001195T3 (es) 2025-03-04
PL3551631T3 (pl) 2025-03-24
HUE070078T2 (hu) 2025-05-28
IL267276B2 (en) 2024-09-01
DK3551631T3 (en) 2025-02-17
US20230330103A1 (en) 2023-10-19
MX2019006942A (es) 2019-10-21
EP3551631B1 (en) 2024-11-13
FI3551631T3 (fi) 2025-01-16
EP4494705A3 (en) 2025-04-02
EP3551631B9 (en) 2025-02-26
JP2020500924A (ja) 2020-01-16
US11491165B2 (en) 2022-11-08
RU2019120162A3 (https=) 2021-01-28
WO2018107216A1 (en) 2018-06-21
IL267276A (en) 2019-08-29
PT3551631T (pt) 2024-12-10
SI3551631T1 (sl) 2025-03-31
AU2017377653A1 (en) 2019-07-11
KR20190091534A (ko) 2019-08-06
EP4494705A2 (en) 2025-01-22
JP7089649B2 (ja) 2022-06-23
NZ754890A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
RU2750148C1 (ru) Соединения, пригодные для использования в качестве ингибиторов atr киназы
US20230330103A1 (en) Non-peptide oxytocin receptor agonists
CN104203914B (zh) 作为lsd1抑制剂的(杂)芳基环丙胺化合物
CA2168432C (en) Piperazine compounds used in therapy
CN113527293A (zh) Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途
MX2014014563A (es) Formas solidas de un compuesto antiviral.
WO2014152018A1 (en) Octahydrocyclopentapyrroles, their preparation and use
JP2015504900A (ja) 複素環式化合物およびその使用方法
CN104418842B (zh) 取代的吲哚化合物及其使用方法和用途
TW201741316A (zh) 四氫異喹啉衍生物
WO2003057223A9 (en) Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
JP6826993B2 (ja) 複素環化合物およびその使用方法
JP2000506524A (ja) フィブリノーゲン受容体拮抗剤であるＮ―［（Ｒ）―１―｛３―（４―ピペリジル）プロピオニル｝―３―ピペリジルカルボニル］―２（Ｓ）―アセチルアミノ―β―アラニン
CN115515959A (zh) 用作tead结合剂的三环杂环
AU2018340867B2 (en) Metabolite inspired selective oxytocin receptor agonists
HK40014275A (en) Non-peptide oxytocin receptor agonists
WO2022161416A1 (zh) 一种芳香化合物、其制备方法及应用
CN118414327A (zh) 作为选择性phd1抑制剂的吡啶酰胺化合物、组合物和使用方法
CA3233083A1 (en) Small molecules for dot1l degradation and uses thereof
CN120569387A (zh) Par2的小分子调节剂及其用途
ITMI942165A1 (it) Derivato della (2-ammino-3, 5-dibromo) benzilammina ad azione antitussiva ed espettorante

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240926

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241128

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241203

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241203

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250827

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251211

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260307

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260307